Scientific ReportsThe clinical significance of phospholipase A2 receptor (PLA2R) antigen domain-specific antibodies has not been determined. We investigated the role of serum PLA2R domain antibodies and epitope spreading in risk stratification and proteinuria remission in
Leting Zhou, Xiran Zhang, Ting Cai
exaly +3 more sources
Annals of MedicineBackground Pathogenic autoantibody subclass switch has been found in lots of autoimmune disease. However, the information on anti-phospholipase A2 receptor antibody subclass switch in membranous nephropathy (MN) is limited and controversial. Here, we aim
Caihong Zeng +2 more
exaly +5 more sources
Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy [PDF]
Biomolecules & BiomedicinePrimary membranous nephropathy (pMN) is a principal cause of nephrotic syndrome in adults. The identification of the M-type phospholipase A2 receptor (PLA2R) antigen has significantly advanced non-invasive management; however, the precise clinical ...
Şenay Yıldırım +5 more
doaj +3 more sources
Renal Failure, 2022 Objective To verify glomerular PLA2R antigen and serum PLA2R antibody expression in membranous nephropathy as well as to explore glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy (IMN) in the background of ...
Xiaoyang Yu, Ping Lan
exaly +3 more sources
Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies [PDF]
Frontiers in ImmunologyBackgroundAbout 30% of patients with phospholipase A2 receptor (PLA2R) associated membranous nephropathy (MN) have negative circulating anti-PLA2R antibodies.
Miao Wang +7 more
doaj +2 more sources
Renal Failure, 2023 Serum anti-phospholipase A2 receptor (anti-PLA2R) antibody is used for the noninvasive diagnosis of idiopathic membranous nephropathy (IMN). However, the cutoff value of anti-PLA2R antibodies in IMN patients is debatable.
Danxia Zheng, Jiansuo Zhou
exaly +3 more sources
Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy [PDF]
Kidney International ReportsIntroduction: The recent Mayo Clinic consensus proposed a target antigen-based diagnostic pathway for membranous nephropathy (MN), recommending testing for neural epidermal growth factor-like 1 (NELL1) following a negative phospholipase A2 receptor ...
Wangyang Li +15 more
doaj +2 more sources
The role of serum BAFF, CFB, MCP-1 and anti-PLA2R antibodies in the efficacy evaluation of patients with membranous nephropathy [PDF]
Journal of Medical BiochemistryBackground: Monocyte chemoattractant protein-1 (MCP-1), serum B-cell activating factor (BAFF), complement B factor (CFB), and anti-M-type phospholipase A2 receptor (PLA2R) antibodies are investigated in relation to membranous nephropathy (MN), and their ...
Zheng Kaiyuan +3 more
doaj +2 more sources
Early kinetics of anti-PLA2R-IgG4 predicts rituximab response in membranous nephropathy: a prospective biomarker study [PDF]
Scientific ReportsWhile anti-PLA2R-IgG4 is a key biomarker in idiopathic membranous nephropathy (IMN), the predictive value of its early kinetics for rituximab (RTX) response is unclear.
Sha Chen +7 more
doaj +2 more sources
Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody [PDF]
PeerJ, 2020 Background To discuss the clinicopathological features and prognosis of patients with idiopathic membranous nephropathy (IMN) who are serum-negative for the anti-PLA2R antibody.
Wenkai Guo +6 more
doaj +2 more sources